Literature DB >> 27096327

The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury.

Cory M Yamashita1,2, Candice Cybulskie1, Scott Milos1, Yi Y Zuo3, Lynda A McCaig1, Ruud A W Veldhuizen1,2.   

Abstract

The acute respiratory distress syndrome (ARDS) is characterized by arterial hypoxemia accompanied by severe inflammation and alterations to the pulmonary surfactant system. Published data has demonstrated a protective effect of matrix metalloproteinase-3 (Mmp3) deficiency against the inflammatory response associated with ARDS; however, the effect of Mmp3 on physiologic parameters and alterations to surfactant have not been previously studied. It was hypothesized that Mmp3 deficient (Mmp3(-/-)) mice would be protected against lung dysfunction associated with ARDS and maintain a functional pulmonary surfactant system. Wild type (WT) and Mmp3(-/-) mice were subjected to acid-aspiration followed by mechanical ventilation. Mmp3(-/-) mice maintained higher arterial oxygenation compared with WT mice at the completion of ventilation. Significant increase in functional large aggregate surfactant forms were observed in Mmp3(-/-) mice compared with WT mice. These findings further support a role of Mmp3 as an attractive therapeutic target for drug development in the setting of ARDS.

Entities:  

Keywords:  acid aspiration; acute lung injury; acute respiratory distress syndrome; aspiration d’acide; hypoxemia; hypoxémie; lésion pulmonaire aiguë; matrix metalloproteinase-3; mechanical ventilation; métalloprotéinase matricielle-3; pulmonary surfactant; surfactant pulmonaire; syndrome de détresse respiratoire aiguë; ventilation mécanique

Mesh:

Substances:

Year:  2016        PMID: 27096327      PMCID: PMC5522962          DOI: 10.1139/cjpp-2015-0377

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  19 in total

Review 1.  The acute respiratory distress syndrome.

Authors:  L B Ware; M A Matthay
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury.

Authors:  R L Warner; L Beltran; E M Younkin; C S Lewis; S J Weiss; J Varani; K J Johnson
Journal:  Am J Respir Cell Mol Biol       Date:  2001-05       Impact factor: 6.914

Review 3.  Pulmonary surfactant: functions and molecular composition.

Authors:  J Goerke
Journal:  Biochim Biophys Acta       Date:  1998-11-19

4.  Biophysical influence of airborne carbon nanomaterials on natural pulmonary surfactant.

Authors:  Russell P Valle; Tony Wu; Yi Y Zuo
Journal:  ACS Nano       Date:  2015-05-06       Impact factor: 15.881

Review 5.  Extracellular metabolism of pulmonary surfactant: the role of a new serine protease.

Authors:  N J Gross
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

Review 6.  Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation.

Authors:  Yi Y Zuo; Ruud A W Veldhuizen; A Wilhelm Neumann; Nils O Petersen; Fred Possmayer
Journal:  Biochim Biophys Acta       Date:  2008-04-08

7.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

8.  Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large-aggregate integrity.

Authors:  R A Veldhuizen; S A Hearn; J F Lewis; F Possmayer
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

Review 9.  Mechanical ventilation: lessons from the ARDSNet trial.

Authors:  A S Slutsky; V M Ranieri
Journal:  Respir Res       Date:  2000-08-31

Review 10.  Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches.

Authors:  Karen J Bosma; Ravi Taneja; James F Lewis
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

View more
  1 in total

1.  Matrix metalloproteinase 3 as a valuable marker for patients with COVID-19.

Authors:  Shengjie Shi; Min Su; Ge Shen; Yan Hu; Fan Yi; Ziyan Zeng; Pan Zhu; Gang Yang; Hui Zhou; Qiong Li; Xiaobing Xie
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.